THE WOODLANDS, Texas – Lexicon Prescribed drugs , Inc. (NASDAQ: NASDAQ:) introduced right this moment that the U.S. Meals and Drug Administration (FDA) has accepted the resubmission of its New Drug Utility (NDA) for Zynquista™ (sotagliflozin).
The drug is being thought of as an adjunct to insulin remedy to enhance glycemic management in adults with sort 1 diabetes and persistent kidney illness (CKD). The FDA has set a Prescription Drug Consumer Payment Act (PDUFA) aim date for a choice on December 20, 2024.
The resubmission is in response to the FDA’s 2019 motion letter concerning the sotagliflozin NDA for sort 1 diabetes. Lexicon believes within the favorable profit/danger profile of sotagliflozin for this affected person inhabitants. Dr. Mike Exton, Lexicon’s CEO, expressed the corporate’s readiness to enter the following part of launch preparation, anticipating the drug’s potential market entry.
Zynquista would mark Lexicon’s second NDA approval and business launch in two years, following the commercialization of INPEFA® (sotagliflozin) in the US. Lexicon’s innovation stems from its Genome5000™ program, which has recognized over 100 protein targets with therapeutic potential in varied illnesses. The corporate goals to securely and successfully deal with illnesses by exactly focusing on these proteins.
The press launch additionally contains forward-looking statements concerning the potential therapeutic and business prospects of sotagliflozin in sort 1 diabetes, in addition to Lexicon’s general monetary well being and future enterprise development. These statements contain dangers and uncertainties, together with the corporate’s potential to safe obligatory capital, efficiently commercialize its merchandise, and procure regulatory approvals on anticipated timelines.
Lexicon has a pipeline of drug candidates in discovery, scientific, and preclinical growth for circumstances comparable to neuropathic ache, diabetes, metabolism, and different indications. The corporate’s progress and techniques are detailed in its annual report on Kind 10-Ok for the yr ended December 31, 2023, and different filings with the Securities and Change Fee.
This text relies on a press launch assertion from Lexicon Prescribed drugs, Inc.
In different latest information, Lexicon Prescribed drugs reported a web lack of $48.4 million in Q1 2024, with a income of $1.1 million. Regardless of this, the corporate efficiently raised $250 million in an oversubscribed providing to assist their applications. When it comes to management modifications, Lexicon Prescribed drugs introduced the appointment of Michael Exton, Ph.D., as the brand new CEO and Jeffrey L. Wade’s promotion to President and Chief Working Officer.
These are latest developments and include important analyst consideration. H.C. Wainwright initiated protection on Lexicon Prescribed drugs with a ‘Purchase’ score, emphasizing the corporate’s dedication to progressive approaches and the potential of its various pipeline. Equally, Piper Sandler reaffirmed its ‘Chubby’ score on Lexicon’s inventory, pointing to the upcoming launch of INPEFA and the growth of sotagliflozin as key catalysts.
Lastly, the corporate supplied full-year expense steerage, projecting R&D bills between $70 million to $80 million and complete working bills starting from $210 million to $235 million. These updates replicate Lexicon Prescribed drugs’ ongoing progress and future plans.
InvestingPro Insights
As Lexicon Prescribed drugs, Inc. (NASDAQ: LXRX) gears up for the anticipated FDA determination on Zynquista™, a better have a look at the corporate’s monetary well being by means of InvestingPro metrics reveals a blended panorama. The corporate’s market cap stands at a modest $766.36 million, reflecting investor sentiment and the dimensions of the enterprise within the biopharmaceutical trade.
From a valuation standpoint, Lexicon’s P/E ratio is unfavorable at -2.48, indicating that the corporate just isn’t at the moment worthwhile. This aligns with the InvestingPro Suggestions, which warning that analysts don’t count on the corporate to be worthwhile this yr.
Furthermore, the corporate’s important income development of 1733.33% over the past twelve months as of Q1 2024 means that Lexicon is increasing its income base, though this development comes from a comparatively small base given the full income of $2.31 million.
InvestingPro Suggestions spotlight that Lexicon holds additional cash than debt on its stability sheet, which is a constructive signal for its monetary stability and talent to fund ongoing operations. Moreover, regardless of the challenges, analysts anticipate gross sales development within the present yr, which might be bolstered by the potential approval and launch of Zynquista™.
For buyers in search of extra in-depth evaluation, there are 13 further InvestingPro Suggestions out there for Lexicon, which might be accessed at: https://www.investing.com/professional/LXRX. The following tips present a broader view of the corporate’s efficiency metrics and future prospects. To discover these insights, use coupon code PRONEWS24 to stand up to 10% off a yearly Professional and a yearly or biyearly Professional+ subscription, enhancing your funding analysis with complete knowledge and skilled evaluation.
This text was generated with the assist of AI and reviewed by an editor. For extra info see our T&C.
